B-intervention	0	6	Guided
I-intervention	7	20	paravertebral
I-intervention	21	27	blocks
O	28	32	with
O	33	39	versus
B-control	40	47	without
I-control	48	57	clonidine
O	58	61	for
O	62	67	women
O	68	78	undergoing
O	79	85	breast
O	86	93	surgery
O	93	94	:
O	95	96	a
O	97	108	prospective
O	109	115	double
O	115	116	-
O	116	123	blinded
O	124	134	randomized
O	135	140	study
O	140	141	.

O	142	155	Paravertebral
O	156	162	blocks
O	163	164	(
O	164	168	PVBs
O	168	169	)
O	170	174	have
O	175	179	been
O	180	190	introduced
O	191	193	as
O	194	196	an
O	197	208	alternative
O	209	211	to
O	212	219	general
O	220	230	anesthesia
O	231	234	for
O	235	241	breast
O	242	248	cancer
O	249	258	surgeries
O	258	259	.

O	260	263	The
O	264	272	addition
O	273	275	of
O	276	285	clonidine
O	286	288	as
O	289	291	an
O	292	300	adjuvant
O	301	303	in
O	304	308	PVBs
O	309	312	may
O	313	320	enhance
O	321	328	quality
O	329	332	and
O	333	341	duration
O	342	344	of
O	345	354	analgesia
O	355	358	and
O	359	372	significantly
O	373	379	reduce
O	380	383	the
O	384	395	consumption
O	396	398	of
O	399	409	analgesics
O	410	415	after
O	416	422	breast
O	423	430	surgery
O	430	431	.

O	432	434	In
O	435	439	this
O	440	451	prospective
O	452	462	randomized
O	463	469	double
O	469	470	-
O	470	475	blind
O	476	481	study
O	481	482	,
O	483	485	we
O	486	494	assessed
O	495	498	the
O	499	511	significance
O	512	514	of
O	515	521	adding
O	522	531	clonidine
O	532	534	to
O	535	538	the
O	539	549	anesthetic
O	550	557	mixture
O	558	561	for
B-eligibility	562	567	women
I-eligibility	568	578	undergoing
I-eligibility	579	589	mastectomy
O	589	590	.

B-total-participants	591	596	Sixty
O	597	605	patients
O	606	610	were
O	611	621	randomized
O	622	629	equally
O	630	634	into
O	635	636	2
O	637	643	groups
O	643	644	,
O	645	649	both
O	650	652	of
O	653	658	which
O	659	667	received
O	668	671	PVB
O	672	677	block
O	677	678	,
O	679	685	either
O	686	690	with
O	691	693	or
O	694	701	without
O	702	711	clonidine
O	711	712	.

O	713	722	Analgesic
O	723	734	consumption
O	735	738	was
O	739	744	noted
O	745	747	up
O	748	750	to
O	751	752	2
O	753	758	weeks
O	759	764	after
O	765	768	the
O	769	778	operation
O	778	779	.

O	780	781	A
O	782	788	visual
O	789	795	analog
O	796	801	scale
O	802	805	was
O	806	810	used
O	811	813	to
O	814	820	assess
O	821	825	pain
O	826	841	postoperatively
O	842	848	during
O	849	852	the
O	853	861	hospital
O	862	866	stay
O	866	867	,
O	868	871	and
O	872	873	a
O	874	881	numeric
O	882	888	rating
O	889	894	scale
O	895	898	was
O	899	903	used
O	904	908	when
O	909	917	patients
O	918	922	were
O	923	933	discharged
O	933	934	.

B-outcome	935	944	Analgesic
I-outcome	945	956	consumption
O	957	960	was
O	961	974	significantly
O	975	980	lower
O	981	983	in
O	984	987	the
O	988	997	clonidine
O	998	1003	group
O	1004	1006	48
O	1007	1012	hours
O	1013	1028	postoperatively
O	1029	1033	with
O	1034	1036	95
O	1036	1037	%
O	1038	1048	confidence
O	1049	1057	interval
O	1058	1059	(
O	1059	1061	CI
O	1061	1062	)
O	1063	1066	for
O	1067	1070	the
O	1071	1081	difference
O	1082	1083	(
O	1083	1084	-
O	1084	1086	69
O	1086	1087	.
O	1087	1088	5
O	1088	1089	%
O	1090	1092	to
O	1093	1094	-
O	1094	1095	6
O	1095	1096	.
O	1096	1097	6
O	1097	1098	%
O	1098	1099	)
O	1099	1100	.

B-outcome	1101	1105	Pain
I-outcome	1106	1112	scores
O	1113	1115	at
O	1116	1120	rest
O	1121	1127	showed
O	1128	1139	significant
O	1140	1149	reduction
O	1150	1152	in
O	1153	1156	the
O	1157	1166	clonidine
O	1167	1172	group
O	1173	1179	during
O	1180	1183	the
O	1184	1190	period
O	1191	1195	from
O	1196	1198	24
O	1199	1201	to
O	1202	1204	72
O	1205	1210	hours
O	1211	1226	postoperatively
O	1227	1231	with
O	1232	1234	95
O	1234	1235	%
O	1236	1238	CI
O	1239	1242	for
O	1243	1246	the
O	1247	1253	ratios
O	1254	1256	of
O	1257	1258	2
O	1259	1264	means
O	1265	1266	(
O	1266	1267	1
O	1267	1268	.
O	1268	1270	09
O	1270	1271	-
O	1271	1272	3
O	1272	1273	.
O	1273	1275	61
O	1275	1276	)
O	1276	1277	,
O	1278	1279	(
O	1279	1280	2
O	1280	1281	.
O	1281	1283	04
O	1283	1284	-
O	1284	1285	9
O	1285	1286	.
O	1286	1288	04
O	1288	1289	)
O	1289	1290	,
O	1291	1294	and
O	1295	1296	(
O	1296	1297	2
O	1297	1298	.
O	1298	1300	54
O	1300	1301	-
O	1301	1303	16
O	1303	1304	.
O	1304	1306	55
O	1306	1307	)
O	1307	1308	,
O	1309	1321	respectively
O	1321	1322	,
O	1323	1327	with
B-outcome	1328	1336	shoulder
I-outcome	1337	1345	movement
O	1346	1348	at
O	1349	1351	24
O	1351	1352	,
O	1353	1355	48
O	1355	1356	,
O	1357	1360	and
O	1361	1363	72
O	1364	1369	hours
O	1370	1385	postoperatively
O	1386	1388	95
O	1388	1389	%
O	1390	1392	CI
O	1393	1396	for
O	1397	1400	the
O	1401	1406	ratio
O	1407	1409	of
O	1410	1411	2
O	1412	1417	means
O	1418	1419	(
O	1419	1420	1
O	1420	1421	.
O	1421	1423	10
O	1423	1424	-
O	1424	1425	3
O	1425	1426	.
O	1426	1428	15
O	1428	1429	)
O	1429	1430	,
O	1431	1432	(
O	1432	1433	1
O	1433	1434	.
O	1434	1436	32
O	1436	1437	-
O	1437	1438	6
O	1438	1439	.
O	1439	1441	38
O	1441	1442	)
O	1442	1443	,
O	1444	1447	and
O	1448	1449	(
O	1449	1450	1
O	1450	1451	.
O	1451	1453	33
O	1453	1454	-
O	1454	1455	8
O	1455	1456	.
O	1456	1458	42
O	1458	1459	)
O	1459	1460	,
O	1461	1473	respectively
O	1473	1474	.

O	1475	1478	The
B-outcome	1479	1483	time
I-outcome	1484	1490	needed
I-outcome	1491	1493	to
I-outcome	1494	1500	resume
I-outcome	1501	1506	daily
I-outcome	1507	1515	activity
O	1516	1519	was
O	1520	1527	shorter
O	1528	1530	in
O	1531	1534	the
O	1535	1544	clonidine
O	1545	1550	group
O	1551	1559	compared
O	1560	1564	with
O	1565	1568	the
O	1569	1576	control
O	1577	1582	group
O	1583	1587	with
O	1588	1590	95
O	1590	1591	%
O	1592	1594	CI
O	1595	1598	for
O	1599	1602	the
O	1603	1608	ratio
O	1609	1611	of
O	1612	1613	2
O	1614	1619	means
O	1620	1621	(
O	1621	1622	1
O	1622	1623	.
O	1623	1625	14
O	1625	1626	-
O	1626	1627	1
O	1627	1628	.
O	1628	1630	62
O	1630	1631	)
O	1631	1632	.

O	1633	1636	The
O	1637	1645	addition
O	1646	1648	of
O	1649	1658	clonidine
O	1659	1667	enhanced
O	1668	1671	the
O	1672	1681	analgesic
O	1682	1690	efficacy
O	1691	1693	of
O	1694	1697	PVB
O	1698	1700	up
O	1701	1703	to
O	1704	1705	3
O	1706	1710	days
O	1711	1726	postoperatively
O	1727	1730	for
O	1731	1739	patients
O	1740	1750	undergoing
O	1751	1757	breast
O	1758	1765	surgery
O	1765	1766	.
